Scarica l'app Stockscreener
13.03
3.62%
-0.49
Dopo l'orario di chiusura:
13.04
0.010
+0.08%
Personalis Inc Borsa (PSNL) Ultime notizie
PSNL|Personalis Inc|Price:11.989|Chg%:+0.209 - TradingKey
Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis - TradingKey
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Personalis Inc (PSNL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempus to buy cancer test maker Personalis for $1.5 billion - AOL.ca
Personalis Inc (PSNL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Personalis Inc (PSNL) Income Statement - TradingKey
Tempus AI buys Personalis for $1.5B; UCSF Health, Kleiner Perkins and Doerr Capital launch health AI accelerator; Candid Health raises $120M - VatorNews
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalpesh Patel: The Fifth MRD Buyout in Less Than a Year - Oncodaily
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Personalis (PSNL) Proxy filing Summary - Quartr
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc.PSNL - The AI Journal
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $16.25 - Moomoo
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL) - Morningstar
Tempus AI buys Personalis for $1.5 billion - grafa.com
Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL) - Seeking Alpha
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal - qz.com
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM) - Seeking Alpha
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus to acquire Personalis - Medical Buyer
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
AI healthcare company acquires US biotech firm for USD 1.7bn - medwatch.com
Personalis (PSNL) Registration Filing Summary - Quartr
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief United States: Meta, Gold, Braemar Hotels & Resorts , AIOS, Alarm.Com Holdings, Personalis Inc, Arcbest Corp, New Horizon Aircraft, Jersey Mike's Subs, Crude Oil and more - Smartkarma
Personalis Price Target Announced at $16.25/Share by Lake Street - Moomoo
AI-Driven Tempus Acquires Cancer Diagnostics Firm Personalis for $1.7B in Stock - Briefs Finance
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Tempus AI Acquires Personalis For $1.5bn To Expand MRD Cancer Testing - insights.citeline.com
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Personalis (NASDAQ: PSNL) agrees to stock-for-stock merger with Tempus AI - Stock Titan
Tempus AI Announces Merger Agreement to Acquire Personalis - TipRanks
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Dea - GuruFocus
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis - MedCity News
Needham cuts Personalis stock rating on Tempus AI acquisition By Investing.com - Investing.com South Africa
Tempus finds time right for $1.5B Personalis MRD grab - BioWorld News
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - TradingView
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis - Latham & Watkins LLP
Personalis Acquisition Price Warranted by Growth Prospects, Needham Says - Moomoo
Needham cuts Personalis stock rating on Tempus AI acquisition - Investing.com UK
Tempus AI stock maintains Buy rating after Personalis acquisition By Investing.com - Investing.com Australia
Tempus AI to acquire Personalis for $1.5B - The Business Journals
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal - TradingView
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink - Barron's
1.13%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):